Kala Pharmaceuticals, Inc. (28)
Browse by Contract Category
Contracts
-
Open Market Sale AgreementSM, dated as of January 19, 2023, by and between Kala Pharmaceuticals, Inc. and Jefferies LLC
(Filed With SEC on January 19, 2023)
-
Third Amendment to Loan and Security Agreement, dated December 27, 2022, by and among Kala Pharmaceuticals, Inc., Combangio, Inc. and Oxford Finance LLC, as collateral agent and...
(Filed With SEC on December 27, 2022)
-
First Amendment to Lease Termination Agreement, dated December 22, 2021, by and between the Registrant and Columbia Massachusetts Arsenal Office Properties, LLC
(Filed With SEC on March 29, 2022)
-
Amendment No. 4 to Commercial Supply Agreement, effective January 6, 2021, by and between the Registrant and Woodstock Sterile Solution, Inc
(Filed With SEC on March 29, 2022)
-
Exclusive License Agreement, dated October 11, 2019, by and between Combangio, Inc. and The Board of Trustees of the Leland Stanford Junior University
(Filed With SEC on March 29, 2022)
-
Agreement and Plan of Merger, dated as of November 15, 2021, by and among Kala Pharmaceuticals, Inc., Ceres Merger Sub, Inc., Combangio, Inc. and, solely in its capacity as...
(Filed With SEC on November 15, 2021)
-
Form of Employee Restricted Stock Unit Award under 2017 Equity Incentive Plan
(Filed With SEC on August 6, 2020)
-
Securities Purchase Agreement, dated November 28, 2022, by and among Kala Pharmaceuticals, Inc. and the purchasers party thereto
(Filed With SEC on November 28, 2022)
-
Form of Series E Preferred Stock Certificate
(Filed With SEC on November 28, 2022)
-
Second Amendment to Loan and Security Agreement, dated May 21, 2022, by and among the Registrant, Combangio, Inc. and Oxford Finance LLC, as collateral agent and lender
(Filed With SEC on August 11, 2022)
-
First Amendment to Loan and Security Agreement, dated November 15, 2021, by and among the Registrant, Combangio, Inc. and Oxford Finance LLC, as collateral agent and lender
(Filed With SEC on August 11, 2022)
-
Asset Purchase Agreement, by and between Kala Pharmaceuticals, Inc., Alcon Pharmaceuticals Ltd. and Alcon Vision, LLC
(Filed With SEC on May 23, 2022)
-
Lease Termination Agreement, dated November 12, 2021, by and between Kala Pharmaceuticals, Inc. and Columbia Massachusetts Arsenal Office Properties, LLC
(Filed With SEC on November 15, 2021)
-
Settlement and License Agreement, dated October 24, 2014, by and between the Registrant and GrayBug, LLC
(Filed With SEC on August 5, 2021)
-
Exclusive License Agreement, dated November 10, 2009, by and between the Registrant and The Johns Hopkins University, as amended by the First Amendment dated November 19, 2012,...
(Filed With SEC on August 5, 2021)
-
Loan and Security Agreement, dated May 4, 2021, by and among Kala Pharmaceuticals, Inc. and Oxford Finance LLC, as collateral agent and lender
(Filed With SEC on May 5, 2021)
-
Amendment No. 3 to Commercial Supply Agreement, dated December 11, 2020, by and between the Registrant and Catalent Pharma Solutions, LLC
(Filed With SEC on February 25, 2021)
-
Amendment No. 1 to Amended and Restated Master Services Agreement, dated August 25, 2020 by and between the Registrant and Altasciences company (formerly Alliance Contract Pharma,...
(Filed With SEC on February 25, 2021)
-
Third Amended and Restated Registration Rights Agreement of the Registrant dated April 4, 2016, as amended by Amendment No. 1 dated December 13, 2017, of the Registrant
(Filed With SEC on February 25, 2021)
-
Fifth Amendment to Exclusive License Agreement, date July 6, 2020, by and between the Johns Hopkins University and the Registrant
(Filed With SEC on August 6, 2020)
-
Form of Non-Employee Director Deferred Restricted Stock Unit Award under 2017 Equity Incentive Plan
(Filed With SEC on May 7, 2020)
-
Form of Non-Employee Director Restricted Stock Unit Award under 2017 Equity Incentive Plan
(Filed With SEC on May 7, 2020)
-
Amendment No. 2 to Commercial Supply Agreement, dated March 27, 2020, by and between the Registrant and Catalent Pharma Solutions, LLC
(Filed With SEC on May 7, 2020)
-
Underwriting Agreement, dated March 10, 2020, by and among Kala Pharmaceuticals, Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and Jefferies LLC, as representatives of...
(Filed With SEC on March 12, 2020)
-
Description of the Registrants Securities Registered under Section 12 of the Exchange Act
(Filed With SEC on February 12, 2020)
-
Amended and Restated 2017 Employee Stock Purchase Plan
(Filed With SEC on May 9, 2019)
-
Form of Amendment to Offer Letters
(Filed With SEC on March 12, 2019)
-
Amended and Restated 2017 Employee Stock Purchase Plan
(Filed With SEC on March 12, 2019)